A recent study published in Diabetes Technology & Therapeutics has demonstrated that the off-label use of semaglutide and ...
Pharmaceutical Technology on MSN2d
Viking strikes $150m deal to secure supply of obesity drugViking Therapeutics has inked a $150m multi-year manufacturing deal with CordenPharma to secure the future supply of its ...
In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...
Compounding pharmacies faced a major setback in their case over the FDA’s decision to remove the obesity drug tirzepatide ...
Meanwhile, tirzepatide-treated patients saw their weight ... agreeing to buy the biotech for around $286m. Bryan Hill, life sciences chief technology officer at Cognizant, discusses how generative ...
A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...
The biotech shared (PDF ... Ascletis is testing ASC47 in combination with tirzepatide and semaglutide, the active ingredients in Lilly’s Zepbound and Novo’s Wegovy, respectively.
Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...
AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback